QRG Capital Management Inc. Boosts Stock Position in Johnson & Johnson $JNJ

by · The Markets Daily

QRG Capital Management Inc. increased its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 5.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 440,815 shares of the company’s stock after purchasing an additional 23,837 shares during the quarter. Johnson & Johnson makes up approximately 0.8% of QRG Capital Management Inc.’s holdings, making the stock its 21st largest holding. QRG Capital Management Inc.’s holdings in Johnson & Johnson were worth $111,954,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Silver Coast Investments LLC increased its stake in shares of Johnson & Johnson by 3.8% during the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company’s stock valued at $271,000 after buying an additional 39 shares during the period. Townsend Asset Management Corp NC ADV lifted its stake in Johnson & Johnson by 0.6% in the second quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company’s stock worth $1,630,000 after acquiring an additional 39 shares during the period. Triumph Capital Management boosted its holdings in Johnson & Johnson by 1.6% in the second quarter. Triumph Capital Management now owns 2,531 shares of the company’s stock valued at $643,000 after acquiring an additional 39 shares in the last quarter. Denali Advisors LLC increased its position in Johnson & Johnson by 1.2% during the 2nd quarter. Denali Advisors LLC now owns 3,305 shares of the company’s stock valued at $839,000 after purchasing an additional 40 shares during the period. Finally, Beaird Harris Wealth Management LLC raised its holdings in Johnson & Johnson by 1.8% in the 4th quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company’s stock worth $501,000 after purchasing an additional 42 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on JNJ shares. Royal Bank Of Canada lifted their target price on shares of Johnson & Johnson from $265.00 to $287.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. UBS Group reissued a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday. Guggenheim upped their target price on Johnson & Johnson from $270.00 to $287.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Citigroup raised their target price on Johnson & Johnson from $285.00 to $298.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Finally, Scotiabank restated an “outperform” rating and set a $305.00 price target on shares of Johnson & Johnson in a research report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $274.13.

View Our Latest Stock Analysis on Johnson & Johnson

Johnson & Johnson Stock Down 0.1%

NYSE:JNJ traded down $0.18 during mid-day trading on Wednesday, hitting $269.01. 6,371,746 shares of the company’s stock were exchanged, compared to its average volume of 8,034,880. The company has a market cap of $648.28 billion, a PE ratio of 31.17, a P/E/G ratio of 2.57 and a beta of 0.24. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. Johnson & Johnson has a one year low of $175.74 and a one year high of $281.07. The business has a fifty day moving average price of $264.30 and a 200 day moving average price of $247.03.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. During the same quarter last year, the firm earned $2.77 earnings per share. The business’s revenue for the quarter was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities analysts predict that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a dividend of $1.34 per share. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson’s payout ratio is presently 62.11%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

  • Positive Sentiment: New Phase 3 modeling for the TECVAYLI plus DARZALEX FASPRO combination estimated that approximately 87% of eligible relapsed/refractory multiple myeloma patients could reach mortality risk comparable to the general population. The analysis also projected nearly four times longer median survival versus standard care, supporting the long-term commercial potential of J&J’s oncology portfolio. MajesTEC-3 analysis
  • Positive Sentiment: J&J’s recently approved ICOTYDE psoriasis treatment expands its immunology growth pipeline beyond oncology and MedTech. Its ongoing Phase 3 psoriatic arthritis program could provide an additional growth opportunity as STELARA sales decline after loss of exclusivity. ICOTYDE immunology push
  • Positive Sentiment: Positive Phase 3 results for CAPLYTA in bipolar I mania strengthen the case that J&J’s Intra-Cellular acquisition can broaden the drug’s use beyond bipolar depression. Approval and commercial execution remain future catalysts. CAPLYTA bipolar study
  • Neutral Sentiment: Analysts continue to favor J&J’s dividend durability and diversified pipeline, but the stock’s strong 12-month performance and elevated valuation may already reflect much of the expected improvement. Healthcare dividend roundup
  • Negative Sentiment: Investor debate remains focused on whether portfolio streamlining, including a potential sale of the orthopedics business, can accelerate growth without sacrificing scale or future MedTech opportunities. The market’s reaction to OTTAVA also underscores the need for stronger execution in MedTech. Potential orthopedics divestiture

Insider Buying and Selling

In other news, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Elizabeth Forminard sold 15,918 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president owned 16,994 shares of the company’s stock, valued at $4,367,458. The trade was a 48.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Read More